<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7319457</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkaa216</article-id>
    <article-id pub-id-type="publisher-id">gkaa216</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SynergyFinder 2.0: visual analytics of multi-drug combination synergies</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Ianevski</surname>
          <given-names>Aleksandr</given-names>
        </name>
        <!--<email>aleksandr.ianevski@helsinki.fi</email>-->
        <aff><institution>Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki</institution>, FI-00290 Helsinki, <country country="FI">Finland</country></aff>
        <aff><institution>Helsinki Institute for Information Technology (HIIT), Department of Computer Science, Aalto University</institution>, FI-02150 Espoo, <country country="FI">Finland</country></aff>
        <xref ref-type="corresp" rid="COR2"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Giri</surname>
          <given-names>Anil K</given-names>
        </name>
        <!--<email>anil.kumar@helsinki.fi</email>-->
        <aff><institution>Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki</institution>, FI-00290 Helsinki, <country country="FI">Finland</country></aff>
        <xref ref-type="corresp" rid="COR3"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0886-9769</contrib-id>
        <name>
          <surname>Aittokallio</surname>
          <given-names>Tero</given-names>
        </name>
        <!--<email>tero.aittokallio@helsinki.fi</email>-->
        <aff><institution>Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki</institution>, FI-00290 Helsinki, <country country="FI">Finland</country></aff>
        <aff><institution>Helsinki Institute for Information Technology (HIIT), Department of Computer Science, Aalto University</institution>, FI-02150 Espoo, <country country="FI">Finland</country></aff>
        <aff><institution>Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital</institution>, N-0310 Oslo, <country country="NO">Norway</country></aff>
        <aff><institution>Oslo Centre for Biostatistics and Epidemiology (OCBE), Faculty of Medicine, University of Oslo</institution>, N-0317 Oslo, <country country="NO">Norway</country></aff>
        <xref ref-type="corresp" rid="COR1"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +358 50 3182426; Email: <email>tero.aittokallio@helsinki.fi</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Aleksandr Ianevski. Email: <email>aleksandr.ianevski@helsinki.fi</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Anil K. Giri. Email: <email>anil.kumar@helsinki.fi</email></corresp>
    </author-notes>
    <pub-date pub-type="ppub">
      <day>02</day>
      <month>7</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2020-04-04">
      <day>04</day>
      <month>4</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>04</day>
      <month>4</month>
      <year>2020</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>48</volume>
    <issue>W1</issue>
    <fpage>W488</fpage>
    <lpage>W493</lpage>
    <history>
      <date date-type="accepted">
        <day>25</day>
        <month>3</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>15</day>
        <month>3</month>
        <year>2020</year>
      </date>
      <date date-type="received">
        <day>13</day>
        <month>2</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2020</copyright-year>
      <license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkaa216.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>SynergyFinder (<ext-link ext-link-type="uri" xlink:href="https://synergyfinder.fimm.fi">https://synergyfinder.fimm.fi</ext-link>) is a stand-alone web-application for interactive analysis and visualization of drug combination screening data. Since its first release in 2017, SynergyFinder has become a widely used web-tool both for the discovery of novel synergistic drug combinations in pre-clinical model systems (e.g. cell lines or primary patient-derived cells), and for better understanding of mechanisms of combination treatment efficacy or resistance. Here, we describe the latest version of SynergyFinder (release 2.0), which has extensively been upgraded through the addition of novel features supporting especially higher-order combination data analytics and exploratory visualization of multi-drug synergy patterns, along with automated outlier detection procedure, extended curve-fitting functionality and statistical analysis of replicate measurements. A number of additional improvements were also implemented based on the user requests, including new visualization and export options, updated user interface, as well as enhanced stability and performance of the web-tool. With these improvements, SynergyFinder 2.0 is expected to greatly extend its potential applications in various areas of multi-drug combinatorial screening and precision medicine.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Academy of Finland</institution>
            <institution-id institution-id-type="DOI">10.13039/501100002341</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>292611</award-id>
        <award-id>310507</award-id>
        <award-id>313267</award-id>
        <award-id>326238</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Cancer Society of Finland</institution>
            <institution-id institution-id-type="DOI">10.13039/501100006383</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Sigrid Jusélius Foundation</institution>
            <institution-id institution-id-type="DOI">10.13039/501100006306</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>European Union's Horizon 2020 Research and Innovation Programme</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="6"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Drug combinations have become a standard therapy for various complex diseases, including tuberculosis, malaria, HIV, and most of the advanced cancers (<xref rid="B1" ref-type="bibr">1–5</xref>). This is because multi-targeted treatments can lead to therapeutic benefits both by enhancing the treatment efficacy and by avoiding the acquisition of monotherapy resistance (<xref rid="B6" ref-type="bibr">6</xref>). Furthermore, in some cases, combinatorial treatments can be administered at lower doses of single drugs that would lead to intolerable dose ranges if used as monotherapies (<xref rid="B7" ref-type="bibr">7</xref>), thus reducing treatment side-effects. High-throughput combinatorial screening is an established approach to identify new synergistic drug combinations, i.e. combinations that result in a higher than expected effects (<xref rid="B8" ref-type="bibr">8</xref>). The degree of combination synergy, or antagonism, is quantified by comparing the observed drug combination response against the expected response, calculated using a reference model that assumes no interaction between drugs. The commonly-used reference models include the highest single agent (HSA) (<xref rid="B9" ref-type="bibr">9</xref>), Bliss (<xref rid="B10" ref-type="bibr">10</xref>), Loewe (<xref rid="B11" ref-type="bibr">11</xref>) and Zero interaction potency (ZIP) model (<xref rid="B12" ref-type="bibr">12</xref>). Drug combinations showing the highest synergy among all the combinations screened are then selected for further development and testing toward safe and effective treatment options. Hence, easy-to-use tools that enable unbiased identification of synergistic combinations from high-throughput experimental data are highly needed for systematic and reproducible discovery process.</p>
    <p>To address this need, we implemented SynergyFinder (<xref rid="B13" ref-type="bibr">13</xref>), a web-application that enables researchers to pre-process, analyze and visualise pairwise drug combinations in an interactive manner. SynergyFinder scores drug combination synergy based on user's selection among the various reference models, and the web-tool supports interactive exploration and comparison of the synergy results. In addition to quantifying the overall synergies, SynergyFinder highlights the dose ranges with the strongest synergy or antagonism for more detailed analyses and interpretation about the clinical feasibility of the combination treatment. Since its initial release, SynergyFinder has been used in a wide range of precision medicine applications, including targeted drug combination discovery (<xref rid="B14" ref-type="bibr">14–16</xref>), drug resistance analysis (<xref rid="B17" ref-type="bibr">17</xref>), finding new vulnerabilities for mutated tumors (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>) and comparative evaluation of synergy scoring models (<xref rid="B20" ref-type="bibr">20</xref>). Furthermore, the open-source SynergyFinder implementation has served as a building block and platform for the development of other drug combination analysis tools, including DECREASE (<xref rid="B21" ref-type="bibr">21</xref>) and SynToxProfiler (<xref rid="B22" ref-type="bibr">22</xref>).</p>
    <p>Currently, the search for combinatorial discoveries is witnessing a paradigm shift from the traditional ‘two drugs in combination’ to the more complex ‘multi-drug cocktails’ (<xref rid="B23" ref-type="bibr">23–29</xref>). As a result, higher-order combination therapies involving three or more drugs have been approved or investigated for multiple diseases (e.g. cancers, HIV and tuberculosis) (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>). For example, a so-called R-CHOP therapy that involves five drugs is an approved curative therapy for Diffuse Large B-Cell Lymphoma (<xref rid="B30" ref-type="bibr">30</xref>). The search for such higher-order synergistic combinations by industry and academia has also led to the generation of dose–response data for a large number of multi-drug combinations (<xref rid="B31" ref-type="bibr">31</xref>). However, most of the tools designed to analyse pairwise combinations do not naturally extend to scoring higher-order interaction, as the mathematical implementation of the reference models (e.g. HSA, Loewe and Bliss model) differs with the addition of each new drug. Furthermore, the visualization of higher-order interactions becomes increasingly complex, and non-intuitive visualizations can easily bias the conclusions about the degree of synergy. Additionally, understanding the contribution of each drug in a cocktail to the joint response requires a systematic assessment of all the sub-combinations (<xref rid="B32" ref-type="bibr">32</xref>). Therefore, there is a need for a software tool that cannot only assess synergy/antagonism of a large number of multi-drug combinations, but also enable an interactive exploration of the synergy patterns for an unbiased analysis of higher-order drug combination experiments.</p>
    <p>Here, we present SynergyFinder version 2.0, an upgraded and improved web-application that enables the analysis of both pairwise and higher-order drug combination data. Based on the users’ requests, SynergyFinder 2.0 implements also novel and improved analysis and visualization options for multi-drug combination data, including automated outlier detection procedure, extended curve-fitting functionality, statistical assessment of replicate measurements, as well as many other enhancements appearing in the latest implementation of SynergyFinder.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>MATERIALS AND METHODS</title>
    <sec id="SEC2-1">
      <title>Overview of the extended functionality of SynergyFinder 2.0</title>
      <p>Details of the original SynergyFinder implementation and its features for synergy assessment between two drugs have been described previously (<xref rid="B13" ref-type="bibr">13</xref>). Here, we primarily focus on the enhancements made to support synergy scoring for higher-order combinations, in addition to other web-tool improvements. More specifically, SynergyFinder 2.0 implements (i) efficient synergy estimation for multi-drug combinations, (ii) various curve-fitting algorithms for single drug dose–responses, (iii) automatic outlier detection in multi-drug combination screening data, (iv) novel visualization and export options and (v) statistical treatment of replicate measurements. A detailed comparison between the features of SynergyFinder release 1.0 and 2.0 is provided in Table <xref rid="tbl1" ref-type="table">1</xref>.</p>
      <table-wrap id="tbl1" orientation="portrait" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Comparison of specific features between SynergyFinder release 1.0 and release 2.0</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Category</th>
              <th rowspan="1" colspan="1">Release 1.0</th>
              <th rowspan="1" colspan="1">Release 2.0</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Synergy assessment</td>
              <td rowspan="1" colspan="1">Two-drug combinations</td>
              <td rowspan="1" colspan="1">Multi-drug combinations (two or more)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Outlier detection</td>
              <td rowspan="1" colspan="1">No</td>
              <td rowspan="1" colspan="1">Yes</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Curve-fitting algorithm</td>
              <td rowspan="1" colspan="1">Four-parameter logistic regression</td>
              <td rowspan="1" colspan="1">Four-parameter logistic regression, linear regression, LOESS fitting</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Replicate analysis</td>
              <td rowspan="1" colspan="1">No</td>
              <td rowspan="1" colspan="1">Yes</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Minimum number of measured drug doses</td>
              <td rowspan="1" colspan="1">Three doses</td>
              <td rowspan="1" colspan="1">One dose</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Visualization options</td>
              <td rowspan="1" colspan="1">2D and 3D interactive surface plots, curve fit plots, heatmaps</td>
              <td rowspan="1" colspan="1">2D and 3D interactive surface plots, curve fit plots, heatmaps, interactive 3D tensor plots, bar graphs</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Reporting</td>
              <td rowspan="1" colspan="1">Static and dynamic reports</td>
              <td rowspan="1" colspan="1">Static, dynamic, and short reports. Simultaneous export of multiple synergy metrics and measured synergy values.</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="SEC2-2">
      <title>SynergyFinder 2.0 analysis of multi-drug combinations</title>
      <p>Similar to SynergyFinder 1.0, version2.0 supports interactive analysis of two-drug combination data, based on the user-uploaded dose–response matrices (Figure <xref ref-type="fig" rid="F1">1A</xref>). As a result, interactive synergy distribution plots, together with summary synergy scores, are generated for each pair of drugs. In addition, SynergyFinder 2.0 supports the analysis of higher-order drug combinations by implementing interactive dose–response tensors for each triplet of the drugs (Figure <xref ref-type="fig" rid="F1">1B</xref>). Furthermore, barplots of synergy scores are produced separately for each sub-combination (pairs, triplets, etc.), depending on the number of drugs in the combinations. For more systematic analysis of the contribution of each drug to the joint higher-order combination effect, 3D synergy landscape plots for each of the two-drug sub-combinations are visualized enabling their further investigation (Figure <xref ref-type="fig" rid="F1">1C</xref>).</p>
      <fig id="F1" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>SynergyFinder 2.0 visual analytic options for (<bold>A</bold>) pairwise combinations and (<bold>B</bold>) higher-order combinations. (<bold>C</bold>) 3D synergy landscapes shown separately for each two-drug sub-combination.</p>
        </caption>
        <graphic xlink:href="gkaa216fig1"/>
      </fig>
      <p>SynergyFinder 2.0. implements four reference synergy models (HSA, Bliss, Loewe and ZIP), and their extensions to calculate synergy scores for higher-order combination data. These models quantify the degree of synergy either as the excess over the maximum single drug response (HSA), multiplicative effect of single drugs as if they acted independently (Bliss), expected response corresponding to an additive effect as if the single drugs were the same compound (Loewe), and expected response corresponding to the effect as if the single drugs did not affect the potency of each other (ZIP). More specifically, the following higher-order formulations were used to quantify the drug combination synergy (<italic>S</italic>) for the measured multi-drug combination effect between <italic>N</italic> drugs <inline-formula><tex-math id="M1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${E_{A,B, \ldots ,N}}$\end{document}</tex-math></inline-formula>:<disp-formula><tex-math id="M2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$$\begin{eqnarray*}\ {S_{HSA}} &amp;=&amp; {E_{A,B, \ldots ,N}}\ - \max ( {{E_A},{E_B}, \ldots ,{E_N}} ).\\\end{eqnarray*}$$\end{document}</tex-math></disp-formula><disp-formula><tex-math id="M3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$$\begin{eqnarray*} {S_{BLISS}} &amp;=&amp; {E_{A,B, \ldots ,N}} - ( {E_A} + {E_B} + \ldots + {E_N} - {E_A}{E_b} \nonumber \\ &amp;&amp;- {E_A}{E_N} - {E_B}{E_N} - \ldots - {E_A}{E_B} \ldots {E_N} ).\\ \end{eqnarray*}$$\end{document}</tex-math></disp-formula><disp-formula><tex-math id="M4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$$\begin{eqnarray*}\ {S_{LOEWE}} &amp;=&amp; \frac{a}{A}\ + \frac{b}{B} + \ldots + \frac{n}{N}.\\\end{eqnarray*}$$\end{document}</tex-math></disp-formula><disp-formula><tex-math id="M5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$$\begin{eqnarray*} {S_{ZIP}} &amp;=&amp; {E_{A,B, \ldots ,N}} - \left( {\frac{{{{\left( {\frac{{{x_A}}}{{{m_A}}}} \right)}^{{{\rm{\lambda }}_A}}}}}{{1 + {{\left( {\frac{{{x_A}}}{{{m_A}}}} \right)}^{{{\rm{\lambda }}_A}}}}} + \frac{{{{\left( {\frac{{{x_B}}}{{{m_B}}}} \right)}^{{{\rm{\lambda }}_B}}}}}{{1 + {{\left( {\frac{{{x_B}}}{{{m_B}}}} \right)}^{{{\rm{\lambda }}_B}}}}} + \ldots} \right.\nonumber \\ &amp;&amp; + \frac{{{{\left( {\frac{{{x_N}}}{{{m_N}}}} \right)}^{{{\rm{\lambda }}_N}}}}}{{1 + {{\left( {\frac{{{x_N}}}{{{m_N}}}} \right)}^{{{\rm{\lambda }}_N}}}}} - \frac{{{{\left( {\frac{{{x_A}}}{{{m_A}}}} \right)}^{{{\rm{\lambda }}_A}}}}}{{1 + {{\left( {\frac{{{x_A}}}{{{m_A}}}} \right)}^{{{\rm{\lambda }}_A}}}}}\frac{{{{\left( {\frac{{{x_B}}}{{{m_B}}}} \right)}^{{{\rm{\lambda }}_B}}}}}{{1 + {{\left( {\frac{{{{\rm{x}}_B}}}{{{m_B}}}} \right)}^{{{\rm{\lambda }}_B}}}}}\nonumber \\ &amp;&amp; - \frac{{{{\left( {\frac{{{x_A}}}{{{m_A}}}} \right)}^{{{\rm{\lambda }}_A}}}}}{{1 + {{\left( {\frac{{{x_A}}}{{{m_A}}}} \right)}^{{{\rm{\lambda }}_A}}}}}\frac{{{{\left( {\frac{{{x_N}}}{{{m_N}}}} \right)}^{{{\rm{\lambda }}_N}}}}}{{1 + {{\left( {\frac{{{x_N}}}{{{m_N}}}} \right)}^{{{\rm{\lambda }}_N}}}}} \nonumber \\ &amp;&amp; - \frac{{{{\left( {\frac{{{x_B}}}{{{m_B}}}} \right)}^{{{\rm{\lambda }}_B}}}}}{{1 + {{\left( {\frac{{{x_B}}}{{{m_B}}}} \right)}^{{{\rm{\lambda }}_B}}}}}\frac{{{{\left( {\frac{{{x_N}}}{{{m_N}}}} \right)}^{{{\rm{\lambda }}_N}}}}}{{1 + {{\left( {\frac{{{x_N}}}{{{m_N}}}} \right)}^{{{\rm{\lambda }}_N}}}}} - \ldots \nonumber \\ &amp;&amp; \left.- \frac{{{{\left( {\frac{{{x_A}}}{{{m_A}}}} \right)}^{{{\rm{\lambda }}_A}}}}}{{1 + {{\left( {\frac{{{x_A}}}{{{m_A}}}} \right)}^{{{\rm{\lambda }}_A}}}}}\frac{{{{\left( {\frac{{{x_B}}}{{{m_B}}}} \right)}^{{{\rm{\lambda }}_B}}}}}{{1 + {{\left( {\frac{{{x_B}}}{{{m_B}}}} \right)}^{{{\rm{\lambda }}_B}}}}} \ldots \frac{{{{\left( {\frac{{{x_N}}}{{{m_N}}}} \right)}^{{{\rm{\lambda }}_N}}}}}{{1 + {{\left( {\frac{{{x_N}}}{{{m_N}}}} \right)}^{{{\rm{\lambda }}_N}}}}} \right). \end{eqnarray*}$$\end{document}</tex-math></disp-formula></p>
      <p>Here, <inline-formula><tex-math id="M6">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${E_A},{E_B}, \ldots ,{E_N}$\end{document}</tex-math></inline-formula> are the measured responses of the single drugs, while <italic>a</italic>, <italic>b</italic> and <italic>n</italic> are the doses of the single drugs required to produce the combination effect <inline-formula><tex-math id="M7">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${E_{A,B, \ldots ,N}}$\end{document}</tex-math></inline-formula>. For the ZIP model, <inline-formula><tex-math id="M8">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${x_N}$\end{document}</tex-math></inline-formula> is the dose of <italic>N</italic><sup>th</sup> drug fitted with four-parameter log-logistic (4PL) function, whereas <inline-formula><tex-math id="M9">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${m_N}$\end{document}</tex-math></inline-formula> is the dose that produces the half-maximum effect (also known as relative <inline-formula><tex-math id="M10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$E{C_{50}}$\end{document}</tex-math></inline-formula> or <inline-formula><tex-math id="M11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$I{C_{50}}$\end{document}</tex-math></inline-formula>, depending on the readout), and <inline-formula><tex-math id="M12">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\rm{\lambda }}_N}$\end{document}</tex-math></inline-formula> is the shape parameter indicating the slope of the dose–response curve.</p>
    </sec>
    <sec id="SEC2-3">
      <title>Curve fitting and outlier detection in drug screening data</title>
      <p>Accurate fitting of the dose–response curves is the first necessary step for any synergy assessment, since the fitted dose-response values are used for outlier detection and calculation of expected effects using the reference models (e.g. Bliss). The most commonly-used curve-fitting model for single-drug dose–responses is the four-parameter logistic (4PL) equation (<xref rid="B33" ref-type="bibr">33–35</xref>), which is also the default option in SynergyFinder. However, since some drug dose–responses may not accurately follow the 4PL model (e.g. U-shaped curves), SynergyFinder 2.0 allows users also to apply LOESS fit and linear regression as alternative algorithms for curve fitting. In case of replicate measurements, the dose–response curves are fitted using all the replicates, hence improving the robustness against outliers.</p>
      <p>For automated detection of outlier measurements both in the combination and individual agent dose–response measurements, we utilized our recently-developed machine learning model, which is built on novel composite non-negative matrix factorization (cNMF) algorithm (<xref rid="B21" ref-type="bibr">21</xref>). More specifically, SynergyFinder 2.0 uses the cNMF algorithm to capture the overall combination patterns and to predict the full dose–response tensors for each combination. Then, the predicted responses are compared against the observed ones, and the user is alerted about any measurements that deviate &gt;20% inhibition from the measured inhibition level as possible outlier measurements. The synergy calculations and visualizations can be performed with or without using the outlier measurements.</p>
    </sec>
    <sec id="SEC2-4">
      <title>SynergyFinder 2.0 input and output options</title>
      <p>SynergyFinder 2.0 allows two possible drug screening data input file formats (Table and Matrix), with the file extensions either as *.xlsx, *.csv or *.txt files. More information about the input data format is given in the technical documentation available at <ext-link ext-link-type="uri" xlink:href="https://synergyfinder.fimm.fi">https://synergyfinder.fimm.fi</ext-link>, ‘User guide’ button. Due to the various combination matrix layouts and experimental designs applied in screening projects, SynergyFinder 2.0 does not impose any restrictions on the drug combination design. Unlike the previous versions, the new version accepts both the ‘full combination designs’, where each drug is measured at multiple doses (<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>), as well as ‘partial combination designs’, where only a fixed single dose is used for any given drug (<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B38" ref-type="bibr">38</xref>). However, in the partial designs, only the Bliss and HSA synergy scores can be calculated, since Loewe and ZIP models require multiple doses for fitting dose–response curves of each drug in the combination. In the case of replicate measurements, SynergyFinder 2.0 also reports standard deviations for each synergy score, which enable statistical analyses of the combination effects.</p>
      <p>For each multi-drug combination, SynergyFinder 2.0 quantifies the selected synergy scores for each combination of single-drug concentration mixtures, in addition to calculating the summary synergy level for the combination effect, i.e. the average of synergy scores over all the measured (non-outlier) concentrations. SynergyFinder 2.0 generates three types of summary PDF reports, which show subsets of the drug combinations, depending on the user's choices. For higher-order combinations, each triplet of drugs is visualized using 3D the dose–response tensor (Figure <xref ref-type="fig" rid="F1">1B</xref>), while separate 2D and 3D synergy landscapes between each pairs of two drugs are generated at different concentrations of <italic>N</italic>th drug (Figure <xref ref-type="fig" rid="F1">1C</xref>). The summary synergy scores between all the sub-combinations of drugs (pairs, triplets, etc) are visualized as summary barplots. Based on the user requests, one can also simultaneously export alternative summary tables (e.g. tables of multiple synergy scores and raw synergy results). These tables allow users to process the synergy results in other analytical or graphical software.</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="SEC3">
    <title>CONCLUSIONS</title>
    <p>We have implemented SynergyFinder version 2.0, a web-based application that enables the users to interactively assess, explore and visualize synergy in multi-drug combination assays. By allowing users to select various functions to fit the dose–response curves, cleaned by automated outlier detection procedure, SynergyFinder provides a flexible and robust solutions for an efficient and reproducible synergy scoring and visualization of multi-drug combinations from high-throughput screens. The use of multiple reference models to estimate synergy will also enable an unbiased evaluation of the pre-clinical significance of combinations toward further development for clinical applications. The web-tool facilitates both the drug combination discovery and screening programs, as it serves as the single point solution supporting multiple aspects of high-throughput combinatorial screening (e.g. outlier detection, curve fitting, and synergy scoring), thereby significantly reducing the time needed for the data analysis and interpretation. SynergyFinder 2.0 helps to assess the synergy scores for any <italic>N</italic>th order combinations, with the only restriction that all the corresponding single-drug responses should be measured at least with one concentration. We recommend using multi-dose assays for more accurate synergy landscape analyses, whereas fixed single-dose designs can be used for initial candidate screening. For two-drug combinations, one can also use our DECREASE model to predict the full dose–response matrices based on the more cost-effective fixed-dose or diagonal designs (<xref rid="B21" ref-type="bibr">21</xref>). We encourage users of SynergyFinder to continue leaving comments or suggestions for further improvements using the feedback form available on the website, as well as implement or request extended functionality through GitHub repository, with the aim of making SynergyFinder even more interactive and user-friendly.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC4">
    <title>DATA AVAILABILITY</title>
    <p>SynergyFinder 2.0 is an open-source software freely available at <ext-link ext-link-type="uri" xlink:href="https://synergyfinder.fimm.fi">https://synergyfinder.fimm.fi</ext-link> without any login requirements. The software comes with example drug combination data, video tutorial and technical user instructions. The source codes of the web-application implementation are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/IanevskiAleksandr/SynergyFinder">https://github.com/IanevskiAleksandr/SynergyFinder</ext-link> (under the BSD 3-clause license) to allow extension of the tool for further applications and integration with other software solutions.</p>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p>We thank the users of SynergyFinder for their valuable suggestions and requests regarding further extensions of the tool. We also thank Dr Jing Tang and Ms. Shuyu Zheng (University of Helsinki) for many fruitful discussions about synergy scoring, as well as our collaborators and colleagues at FIMM, namely Jani Saarela, Swapnil Potdar, and Laura Turunen, for careful beta-testing of the SynergyFinder release 2.0, and for their valuable suggestions on how to improve the web-tool and make it more user-friendly. We also thank Olle Hansson for his help with the domain name and FIMM server machine support.</p>
    <p><italic>Authors’ contributions</italic>: A.I. designed the study. T.A., A.I. and A.K.G. wrote the manuscript. A.I. engineered the web server. A.K.G. and T.A. supervised the project.</p>
  </ack>
  <sec id="SEC5">
    <title>FUNDING</title>
    <p>Academy of Finland [292611, 310507, 313267, 326238 to T.A.]; Cancer Society of Finland [to T.A.]; Sigrid Jusélius Foundation [to TA]. Funding for open access charge: European Union's Horizon 2020 Research and Innovation Programme [ERA PerMed JAKSTAT-TARGET project].</p>
    <p><italic>Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Boeree</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hermann</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Hoelscher</surname><given-names>M.</given-names></name></person-group><article-title>Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: new technologies and innovative designs</article-title>. <source>PLoS Med.</source><year>2019</year>; <volume>16</volume>:<fpage>e1002851</fpage>.<pub-id pub-id-type="pmid">31287813</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adam</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Gasim</surname><given-names>G.I.</given-names></name></person-group><article-title>Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis</article-title>. <source>Malar. J.</source><year>2018</year>; <volume>17</volume>:<fpage>110</fpage>.<pub-id pub-id-type="pmid">29534720</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Properzi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Magro</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Castelli</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Quiros-Roldan</surname><given-names>E.</given-names></name></person-group><article-title>Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults</article-title>. <source>Expert Rev. Anti Infect. Ther.</source><year>2018</year>; <volume>16</volume>:<fpage>877</fpage>–<lpage>887</lpage>.<pub-id pub-id-type="pmid">30392419</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Martinez-Romero</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kouznetsova</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Tawa</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Shinn</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Motabar</surname><given-names>O.</given-names></name><etal>et al</etal>.</person-group><article-title>Synergistic drug combination effectively blocks Ebola virus infection</article-title>. <source>Antiviral Res.</source><year>2017</year>; <volume>137</volume>:<fpage>165</fpage>–<lpage>172</lpage>.<pub-id pub-id-type="pmid">27890675</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotwals</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Cameron</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Cipolletta</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Cremasco</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Crystal</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hewes</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Mueller</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Quaratino</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Sabatos-Peyton</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Petruzzelli</surname><given-names>L.</given-names></name><etal>et al</etal>.</person-group><article-title>Prospects for combining targeted and conventional cancer therapy with immunotherapy</article-title>. <source>Nat. Rev. Cancer</source>. <year>2017</year>; <volume>17</volume>:<fpage>286</fpage>–<lpage>301</lpage>.<pub-id pub-id-type="pmid">28338065</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>K. B.</given-names></name>, <name name-style="western"><surname>Wood</surname><given-names>K. C.</given-names></name>, <name name-style="western"><surname>Nishida</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Cluzel</surname><given-names>P.</given-names></name></person-group><article-title>Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells</article-title>. <source>Cell Rep.</source><year>2014</year>; <volume>6</volume>:<fpage>1073</fpage>–<lpage>1084</lpage>.<pub-id pub-id-type="pmid">24613352</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Law</surname><given-names>M.R.</given-names></name>, <name name-style="western"><surname>Wald</surname><given-names>N.J.</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>J.K.</given-names></name>, <name name-style="western"><surname>Jordan</surname><given-names>R.E.</given-names></name></person-group><article-title>Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials</article-title>. <source>BMJ</source>. <year>2003</year>; <volume>28</volume>:<volume>326</volume>:<fpage>1427</fpage>.</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holbeck</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Camalier</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Crowell</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>Govindharajulu</surname><given-names>J.P.</given-names></name>, <name name-style="western"><surname>Hollingshead</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>L.W.</given-names></name>, <name name-style="western"><surname>Polley</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Rubinstein</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Wilsker</surname><given-names>D.</given-names></name><etal>et al</etal>.</person-group><article-title>The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity</article-title>. <source>Cancer Res.</source><year>2017</year>; <volume>77</volume>:<fpage>3564</fpage>–<lpage>3576</lpage>.<pub-id pub-id-type="pmid">28446463</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berenbaum</surname><given-names>M.C.</given-names></name></person-group><article-title>What is synergy</article-title>. <source>Pharmacol Rev.</source><year>1990</year>; <volume>41</volume>:<fpage>93</fpage>–<lpage>141</lpage>.</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bliss</surname><given-names>C.I.</given-names></name></person-group><article-title>The toxicity of poisons applied jointly</article-title>. <source>Ann. App. Biol.</source><year>1939</year>; <volume>26</volume>:<fpage>585</fpage>–<lpage>615</lpage>.</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loewe</surname><given-names>S.</given-names></name></person-group><article-title>The problem of synergism and antagonism of combineddrugs</article-title>. <source>ArzneimiettelForschung</source>. <year>1953</year>; <volume>3</volume>:<fpage>286</fpage>–<lpage>290</lpage>.</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Wennerberg</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Aittokallio</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name></person-group><article-title>Searching for drug synergy in complex dose-response landscapes using an interaction potency model</article-title>. <source>Comput. Struct. Biotechnol. J.</source><year>2015</year>; <volume>13</volume>:<fpage>504</fpage>–<lpage>513</lpage>.<pub-id pub-id-type="pmid">26949479</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ianevski</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Aittokallio</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name></person-group><article-title>SynergyFinder: a web application for analyzing drug combination dose-response matrix data</article-title>. <source>Bioinformatics</source>. <year>2017</year>; <volume>33</volume>:<fpage>2413</fpage>–<lpage>2415</lpage>.<pub-id pub-id-type="pmid">28379339</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kivioja</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Thanasopoulou</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kontro</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Yadav</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Majumder</surname><given-names>M.M.</given-names></name>, <name name-style="western"><surname>Javarappa</surname><given-names>K.K.</given-names></name>, <name name-style="western"><surname>Eldfors</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Schwaller</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Porkka</surname><given-names>K.</given-names></name><etal>et al</etal>.</person-group><article-title>Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD(+) acute myeloid leukemia</article-title>. <source>Leukemia</source>. <year>2019</year>; <volume>33</volume>:<fpage>1360</fpage>–<lpage>1372</lpage>.<pub-id pub-id-type="pmid">30568173</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stathias</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Jermakowicz</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Maloof</surname><given-names>M.E.</given-names></name>, <name name-style="western"><surname>Forlin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Walters</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Suter</surname><given-names>R.K.</given-names></name>, <name name-style="western"><surname>Durante</surname><given-names>M.A.</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Harbour</surname><given-names>J.W.</given-names></name>, <name name-style="western"><surname>Volmar</surname><given-names>C.H.</given-names></name><etal>et al</etal>.</person-group><article-title>Drug and disease signature integration identifies synergistic combinations in glioblastoma</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>:<fpage>5315</fpage>.<pub-id pub-id-type="pmid">30552330</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Andersson</surname><given-names>E.I.</given-names></name>, <name name-style="western"><surname>Timonen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Koschmieder</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wennerberg</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Mustjoki</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Aittokallio</surname><given-names>T.</given-names></name></person-group><article-title>Patient-Customized drug combination prediction and testing for T-cell prolymphocytic leukemia patients</article-title>. <source>Cancer Res.</source><year>2018</year>; <volume>78</volume>:<fpage>2407</fpage>–<lpage>2418</lpage>.<pub-id pub-id-type="pmid">29483097</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Roychoudhury</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Biswas</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Mohapatra</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Ray</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Dowlatshahi</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Band</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Talmon</surname><given-names>G.</given-names></name><etal>et al</etal>.</person-group><article-title>Targeting histone chaperone FACT complex overcomes 5-Fluorouracil resistance in colon cancer</article-title>. <source>Mol. Cancer Ther.</source><year>2020</year>; <volume>19</volume>:<fpage>258</fpage>–<lpage>269</lpage>.<pub-id pub-id-type="pmid">31575655</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeselsohn</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Bergholz</surname><given-names>J.S.</given-names></name>, <name name-style="western"><surname>Pun</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Cornwell</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Nardone</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Buchwalter</surname><given-names>G.</given-names></name><etal>et al</etal>.</person-group><article-title>Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations</article-title>. <source>Cancer Cell</source>. <year>2018</year>; <volume>33</volume>:<fpage>173</fpage>–<lpage>186</lpage>.<pub-id pub-id-type="pmid">29438694</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maertens</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Kuzmickas</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Manchester</surname><given-names>H.E.</given-names></name>, <name name-style="western"><surname>Emerson</surname><given-names>C.E.</given-names></name>, <name name-style="western"><surname>Gavin</surname><given-names>A.G.</given-names></name>, <name name-style="western"><surname>Guild</surname><given-names>C.J.</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>T.C.</given-names></name>, <name name-style="western"><surname>De Raedt</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Bowman-Colin</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Hatchi</surname><given-names>E.</given-names></name><etal>et al</etal>.</person-group><article-title>MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1-Mutant melanomas</article-title>. <source>Cancer Discov.</source><year>2019</year>; <volume>9</volume>:<fpage>526</fpage>–<lpage>545</lpage>.<pub-id pub-id-type="pmid">30709805</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlot</surname><given-names>A.H.C.</given-names></name>, <name name-style="western"><surname>Aniceto</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Menden</surname><given-names>M.P.</given-names></name>, <name name-style="western"><surname>Ulrich-Merzenich</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Bender</surname><given-names>A.</given-names></name></person-group><article-title>Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls</article-title>. <source>Drug Discov. Today</source>. <year>2019</year>; <volume>24</volume>:<fpage>2286</fpage>–<lpage>2298</lpage>.<pub-id pub-id-type="pmid">31518641</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ianevski</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Giri</surname><given-names>A.K.</given-names></name>, <name name-style="western"><surname>Gautam</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Kononov</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Potdar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Saarela</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wennerberg</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Aittokallio</surname><given-names>T.</given-names></name></person-group><article-title>Prediction of drug combination effects with a minimal set of experiments</article-title>. <source>Nat. Mach. Intell.</source><year>2019</year>; <volume>1</volume>:<fpage>568</fpage>–<lpage>577</lpage>.<pub-id pub-id-type="pmid">32368721</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ianevski</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Timonen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kononov</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Aittokallio</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Giri</surname><given-names>A.K.</given-names></name></person-group><article-title>SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy</article-title>. <source>PLoS Comput. Biol.</source><year>2020</year>; <volume>16</volume>:<fpage>e1007604</fpage>.<pub-id pub-id-type="pmid">32012154</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chevereau</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Bollenbach</surname><given-names>T.</given-names></name></person-group><article-title>Systematic discovery of drug interaction mechanisms</article-title>. <source>Mol. Syst. Biol.</source><year>2015</year>; <volume>11</volume>:<fpage>807</fpage>.<pub-id pub-id-type="pmid">25924924</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmer</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Katzir</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Dekel</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Mayo</surname><given-names>A.E.</given-names></name>, <name name-style="western"><surname>Alon</surname><given-names>U.</given-names></name></person-group><article-title>Prediction of multidimensional drug dose responses based on measurements of drug pairs</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2016</year>; <volume>13</volume>:<fpage>10442</fpage>–<lpage>10447</lpage>.</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cokol</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kuru</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bicak</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Larkins-Ford</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Aldridge</surname><given-names>B.B.</given-names></name></person-group><article-title>Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis</article-title>. <source>Sci. Adv.</source><year>2017</year>; <volume>3</volume>:<fpage>e1701881</fpage>.<pub-id pub-id-type="pmid">29026882</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Le Roux-Bourdieu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zoetemelk</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ramzy</surname><given-names>G.M.</given-names></name>, <name name-style="western"><surname>Rausch</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Harry</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Miljkovic-Licina</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Falamaki</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Wehrle-Haller</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Meraldi</surname><given-names>P.</given-names></name><etal>et al</etal>.</person-group><article-title>Identification of a synergistic Multi-Drug combination active in cancer cells via the prevention of spindle pole clustering</article-title>. <source>Cancers (Basel)</source>. <year>2019</year>; <volume>11</volume>:<comment>doi:10.3390/cancers11101612</comment>.</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amzallag</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ramaswamy</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Benes</surname><given-names>C.H.</given-names></name></person-group><article-title>Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets</article-title>. <source>BMC Bioinformatics</source>. <year>2019</year>; <volume>20</volume>:<fpage>83</fpage>.<pub-id pub-id-type="pmid">30777010</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lukacisin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Bollenbach</surname><given-names>T.</given-names></name></person-group><article-title>Emergent gene expression responses to drug combinations predict Higher-Order drug interactions</article-title>. <source>Cell Syst.</source><year>2019</year>; <volume>9</volume>:<fpage>423</fpage>–<lpage>433</lpage>.<pub-id pub-id-type="pmid">31734160</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katzir</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Cokol</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Aldridge</surname><given-names>B.B.</given-names></name>, <name name-style="western"><surname>Alon</surname><given-names>U.</given-names></name></person-group><article-title>Prediction of ultra-high-order antibiotic combinations based on pairwise interactions</article-title>. <source>PLoS Comput. Biol.</source><year>2019</year>; <volume>15</volume>:<fpage>e1006774</fpage>.<pub-id pub-id-type="pmid">30699106</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakhtakia</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Burney</surname><given-names>I.</given-names></name></person-group><article-title>A historical tale of two Lymphomas: part II: non-Hodgkin lymphoma</article-title>. <source>Sultan Qaboos Univ. Med. J.</source><year>2015</year>; <volume>15</volume>:<fpage>e317</fpage>–<lpage>321</lpage>.<pub-id pub-id-type="pmid">26355399</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tekin</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>White</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>T.M.</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Cruz-Loya</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Damoiseaux</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>V.M.</given-names></name>, <name name-style="western"><surname>Yeh</surname><given-names>P.J.</given-names></name></person-group><article-title>Prevalence and patterns of higher-order drug interactions in Escherichia coli</article-title>. <source>NPJ Syst. Biol Appl.</source><year>2018</year>; <volume>4</volume>:<fpage>31</fpage>.<pub-id pub-id-type="pmid">30181902</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foucquier</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Guedj</surname><given-names>M.</given-names></name></person-group><article-title>Analysis of drug combinations: current methodological landscape</article-title>. <source>Pharmacol. Res. Perspect.</source><year>2015</year>; <volume>3</volume>:<fpage>e00149</fpage>.<pub-id pub-id-type="pmid">26171228</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Veroli</surname><given-names>G.Y.</given-names></name>, <name name-style="western"><surname>Fornari</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Goldlust</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Mills</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Koh</surname><given-names>S.B.</given-names></name>, <name name-style="western"><surname>Bramhall</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>F.M.</given-names></name>, <name name-style="western"><surname>Jodrell</surname><given-names>D.I.</given-names></name></person-group><article-title>An automated fitting procedure and software for dose-response curves with multiphasic features</article-title>. <source>Sci. Rep.</source><year>2015</year>; <volume>5</volume>:<fpage>14701</fpage>.<pub-id pub-id-type="pmid">26424192</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbas-Aghababazadeh</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Fridley</surname><given-names>B.L.</given-names></name></person-group><article-title>Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines</article-title>. <source>Sci. Rep.</source><year>2019</year>; <volume>9</volume>:<fpage>14421</fpage>.<pub-id pub-id-type="pmid">31594982</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gadagkar</surname><given-names>S.R.</given-names></name>, <name name-style="western"><surname>Call</surname><given-names>G.B.</given-names></name></person-group><article-title>Computational tools for fitting the Hill equation to dose–response curves</article-title>. <source>J. Pharmacol. Toxicol. Methods</source>. <year>2015</year>; <volume>71</volume>:<fpage>68</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">25157754</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vascellari</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Valletta</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Perra</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Pinna</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Serra</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Isaia</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Pani</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pivetta</surname><given-names>T.</given-names></name></person-group><article-title>Cisplatin, glutathione and the third wheel: a copper-(1,10-phenanthroline) complex modulates cisplatin–GSH interactions from antagonism to synergism in cancer cells resistant to cisplatin</article-title>. <source>RSC Adv.</source><year>2019</year>; <volume>9</volume>:<fpage>5362</fpage>–<lpage>5376</lpage>.</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Otsman</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Cruz-Loya</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lozano</surname><given-names>N.A.</given-names></name>, <name name-style="western"><surname>Damoiseaux</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>V.M.</given-names></name>, <name name-style="western"><surname>Yeh</surname><given-names>P.J.</given-names></name></person-group><article-title>Transitions in interaction landscapes of multidrug combinations</article-title>. <year>2018</year>; <comment>bioRxiv doi:</comment><comment>11 July 2018, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.1101/367664</pub-id>.</mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cokol</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chandrasekaran</surname><given-names>S.</given-names></name></person-group><article-title>Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment</article-title>. <source>PLoS Comput. Biol.</source><year>2018</year>; <volume>14</volume>:<fpage>e1006677</fpage>.<pub-id pub-id-type="pmid">30596642</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
